Possible transient adaptive response to mitomycin C in peripheral lymphocytes from thyroid cancer patients after iodine‐131 therapy

Abstract

Our study attempted to assess the possible induction and persistence of an adaptive response in lymphocytes of thyroidectomized thyroid cancer patients treated with 131 I (2,590 MBq, corresponding to whole body doses in the range of 200 -300 mGy), to a testing dose of mitomycin C (MMC) in vitro. The cytogenetic endpoint studied was the induction of micronuclei in cytokinesis-blocked peripheral blood lymphocytes, immediately before treatment and 1, 6 and 24 months after therapy. One month after therapy, induction of micronucleated cytokinesis-blocked lymphocytes (‰) by MMC was lower (34.6 ؎ 7.7) than before therapy (52.1 ؎ 5.0). In 7 of 11 patients this reduction was significant. However, at 6 months, induction of micronuclei was markedly higher (133.1 ؎ 13.6). This significant increase was observed regardless of the decrease at 1 month. At 24 months, the frequency of micronucleated cells decreased (84.8 ؎ 5.5), but remained higher than before treatment. The results obtained 1 month after therapy could reflect adaptation due to radiation, or a higher rate of early apoptosis or cell death, with bone marrow suppression, visible as a lower response in vitro towards MMC. At 6 months, recovery of the lymphocyte population may occur, and higher responses to MMC in vitro could reflect higher chromosomal instability in the previously irradiated stem cells with a concomitant disappearance of adaptation, whereas at 24 months the results show a tendency to return to pretherapy values.

Combined effects of Lenvatinib and iodine‑131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress

“…Standard therapies for NPC remain toxic and ineffective ( 26 ). I-131 is known as producing relatively low radiation, and has exhibited anti-cancer effects in several types of human cancer, including thyroid and hepatocellular cancer ( 10 – 12 ). In addition, targeted therapy of LEB has presented the potential to completely eradicate tumors, but with low toxicity to normal human tissues during cancer treatment ( 27 , 28 ).…”

“…Iodine-131 (I-131) therapy has been accepted for the treatment of thyroid cancer due to lower radiation of β-radial and easy excretion. A number of reports have focused on I-131 therapy for the treatment of thyroid cancer ( 10 , 11 ). The efficacy of I-131 has been previously investigated for fewer side effects for patients with cancer.…”

Micronuclei Formation upon Radioiodine Therapy for Well-Differentiated Thyroid Cancer: The Influence of DNA Repair Genes Variants

“…We have previously demonstrated that therapy with 70 mCi 131 I in DTC patients is consistently associated with increased DNA damage levels in peripheral lymphocytes [22,23]. With this study, we aimed to confirm, through the use of the cytokinesis-blocked micronucleus (CBMN) assay, our prior findings in a new group of DTC patients submitted to RAI therapy with 100 mCi.…”

The level of antigen-antibody complexes in thyroid cancer patients in different age groups early after radioiodine therapy

“…Âïëèâ íàâ³òü ìàëèõ äîç ðàä³àö³¿ ñóïðîâîäaeóºòüñÿ ðîçâèòêîì íèçêè çì³í â ³ìóíí³é ñèñòåì³ íà êë³òèííîìó òà ñóáêë³òèííîìó ð³âíÿõ, à äåôåêòè, ùî ñôîðìóâàëèñÿ, ëåaeàòü â îñíîâ³ ïàòîãåíåçó áàãàòüîõ çàõâîðþâàíü. Òàê, ó ë³ìôîöèòàõ êðîâ³ õâîðèõ, ÿê³ ïðîéøëè ë³êóâàííÿ ðàä³îàêòèâíèì éîäîì, âèÿâëåíî ð³çíîìàí³òí³ õðîìîñîìí³ ïîøêîäaeåííÿ, ùî çáåð³ãàþòüñÿ ðîêàìè [7][8][9]. Íàâ³òü íèçüê³ äîçè ðàä³îéîäó, ùî âèêîðèñòîâóþòüñÿ äëÿ ä³àãíîñòè÷íî¿ ñöèíòèãðà-ô³¿, ñóòòºâî çá³ëüøóþòü ê³ëüê³ñòü õðîìîñîìíèõ àáåðàö³é.…”